The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 2, 2010, Pages 759-762

  D'Alessandro, Pier L ^a   Corti, Corrado ^b   Roth, Adelheid ^b   Ugolini, Annarosa ^b   Sava, Anna ^b   Montanari, Dino ^b   Bianchi, Federica ^b   Garland, Stephen L ^a   Powney, Ben ^a   Koppe, Emma L ^a   Rocheville, Magalie ^a   Osborne, Greg ^a   Perez, Paloma ^c   de la Fuente, Jesús ^c   De Los Frailes, Maite ^c   Smith, Paul W ^a   Branch, Clive ^a   Nash, David ^a   Watson, Stephen P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GSK   (Italy)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

Metabotropic glutamate receptor; Metabotropic glutamate receptor ligand; mGlu; mGluR; mGluR2; Positive allosteric modulator

Indexed keywords

GSK 1331258; GSK 1331268; LY 487379; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SYNAPSE;

ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ANIMALS; BENZIMIDAZOLES; DOPAMINE; HIGH-THROUGHPUT SCREENING ASSAYS; PIPERAZINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC POTENTIALS;

RATTUS;

EID: 72249115352     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.032     Document Type: Article

References (26)

1. Lam A.G., Soriano M.A., Monn J.A., Schoepp D.D., Lodge D., and McCulloch J. Neurosci. Lett. 2540 (1998) 121
2. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., and Schoepp D.D. Eur. J. Pharmacol. 377 (1999) 155
3. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., and Kallman M.J. J. Pharmacol. Exp. Ther. 284 (1998) 651
4. Chavez-Noriega L.E., Schaffhauser H., and Campbell U.C. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 261
5. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Nat. Med. 13 (2007) 1102
6. Fell M.L., Svesson K.A., Johnson B.J., and Schoepp D.D. J. Pharmacol. Exp. Ther. 326 (2008) 209
7. Kew J.N.C. Pharm. Theor. 104 (2004) 233
8. Pin J.P., and Acher F. Curr. Drug Targets CNS. Neurol. Disord. 3 (2002) 297-317
9. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizzano J.P., and Schoepp D.D. Psychopharmacology 179 (2005) 271
10. Coleman, D. S.; Jagdmann, G. E. J.; Johnson, K. W.; Johnson, Michael P.; Large, T. H.; Monn, J. A.; Schoepp, D. D.; Tizzano, J. P.; Barda, D. A.; Britton, T. C.; Dressman, B. A.; Fichtner, M. W.; Henry, S. S.; Hornback, W.J. Patent: WO 2001056990.
11. Imogai, H. J.; Cid-Nunez, J. M.; Andres-Gil, J. I.; Trabanco-Suarez, A. A.; Oyarzabal Santamarina, J.; Dautzenberg, F. M.; MacDonald, G. J.; Pullan, S. E.; Luetjens, R. J.; Duvey, G. A. J.; Nhem, V.; F., Terry, P.; Melikyan, G. 2007;Patent: WO 2007104783.
12. Bonnefous C., Vernier J.M., Hutchinson J.H., Gardner M.F., Cramer M., James J.K., Rowe B.A., Daggett L.P., Schaffhauser H., and Kamenecka T.M.J. Bioorg. Med. Chem. Lett. 15 (2005) 4354
13. Rudd M.T., and McCauley J.A. Curr. Top. Med. Chem. 5 (2005) 869
14. Zhang L., Rogers B.N., Duplantier A.J., McHardy S.F., Efremov I., Berke H., Qian W., Zhang A.Q., Maklad N., Candler J., Doran A.C., Lazzaro Jr. J.T., and Ganong A.H. Bioorg. Med. Chem. Lett. 18 (2008) 5493
15. 100 of glutamate.
16. Johnson B.G., Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., and Schoepp D.D. Neuropharmacology 38 (1999) 1519
17. Structure of final compounds confirmed via H NMR and LC-MS analysis.
18. Stewart A.O., Cowart M.D., Moreland R.B., Latshaw S.P., Matulenko M.A., Bhatia P.A., Wang X., Daanen J.F., Nelson S.L., Terranova M.A., Namovic M.T., Donnelly-Roberts D.L., Miller L.N., Nakane M., Sullivan J.P., and Brioni J.D. J. Med. Chem. 47 (2004) 2348
19. Nakane M., Cowart M.D., Hsieh G.C., Miller L., Uchic M.E., Chang R., Terranova M.A., Donnelly-Roberts D.L., Namovic M.T., Miller T.R., Wetter J.M., Marsh K., Stewart A.O., Brioni J.D., and Moreland R.B. Neuropharmacology 49 (2005) 112
20. Cowart M., Latshaw S.P., Bhatia P.A., Daanen J.F., Rohde J.J., Nelson S.L., Patel M.V., Kolasa T., Nakane M., Uchic M.E., Miller L.N., Terranova M.A., Chang R., Donnelly-Roberts D.L., Namovic M.T., Hollingsworth P.R., Martino B.R., Lynch J.J., Sullivan J.P., Hsieh G.C., Moreland R.B., Brioni J.D., and Stewart A.O. J. Med. Chem. 47 (2004) 3853
21. D2 and D3, [35S]-GTPgS assay CHO membranes expressing G0 with hD3 or hD2 transfected; D4 FLIPR assay in HEK293 cells stably expressing hD4 and transiently expressing the chimeric Gqo5 G-protein, Values are typically an average of four or more experiments generated from 11 point dose-response curves.
22. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J.M., Bristow L.J., Varney M.A., and Daggett L.P. Mol. Pharmacol. 64 (2003) 798
23. Kew J.N., Ducarre J.M., Pflimlin M.C., Mutel V., and Kemp J.A. Neuropharmacology 40 (2001) 20
24. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Maynen G., Wu S., Cocherham S.L., Burnett J.P., Belegaje R., Bleakman D., and Monn J.A. Neuropharmacology 36 (1997) 1
25. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., and Schoepp D.D. J. Med. Chem. 42 (1999) 1027
26. GSK1331258 and GSK1331268 showed no significant activity across a panel of representative seratonergic, histaminergic and adrenergic receptors. Activity at mGluR3 was not determined.